Scholar Rock Holding Corporation

Equities

SRRK

US80706P1030

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 09:25:14 29/05/2024 pm IST			5-day change	1st Jan Change
9.83 ^USD	-4.84%		-15.24%	-47.21%

28/05	Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology Annual Meeting	CI
23/05	Transcript : Scholar Rock Holding Corporation Presents at UBS Obesity Therapeutics Day, May-23-2024 09:00 AM

Scholar Rock Holding Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 10, 2023 at 01:45 am IST

Scholar Rock Holding Corporation reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 37.93 million compared to USD 44 million a year ago.
For the six months, net loss was USD 77.3 million compared to USD 51.95 million a year ago.

Latest news about Scholar Rock Holding Corporation

Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology Annual Meeting	28/05	CI
Transcript : Scholar Rock Holding Corporation Presents at UBS Obesity Therapeutics Day, May-23-2024 09:00 AM	23/05
Scholar Rock Starts Phase 2 Trial of Apitegromab in Obesity	22/05	MT
Scholar Rock Holding Corporation Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity	22/05	CI
Scholar Rock Holding Corporation and Scholar Rock, Inc. Enter into the Fourth Amendment to the Loan and Security Agreement	22/05	CI
Transcript : Scholar Rock Holding Corporation - Analyst/Investor Day	22/05
Scholar Rock Shares Fall on Wider-Than-Expected Q1 Loss	07/05	MT
Scholar Rock Holding Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Scholar Rock Shares Rise After Raymond James Initiates Coverage	29/03	MT
Raymond James Initiates Scholar Rock With Strong Buy Rating, $30 Price Target	28/03	MT
Scholar Rock Holding Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	19/03	CI
Scholar Rock Holding Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	19/03	CI
North American Morning Briefing : Investors -2-	18/03	DJ
North American Morning Briefing : Stock Futures -2-	11/03	DJ
Scholar Rock Announces Management Appointments	15/02	CI
Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management	06/02	CI
Scholar Rock Says FDA Clears Application for Trial of Obesity Treatment Apitegromab	23/01	DJ
Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity	23/01	CI
Transcript : Scholar Rock Holding Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 01:30 PM	10/01
Scholar Rock Holding Corporation(NasdaqGS:SRRK) added to S&P Biotechnology Select Industry Index	18/12	CI
Scholar Rock Holding Insider Sold Shares Worth $448,444, According to a Recent SEC Filing	16/12	MT
Certain Common Warrants of Scholar Rock Holding Corporation are subject to a Lock-Up Agreement Ending on 11-DEC-2023.	11/12	CI
Certain Restricted Stock Units of Scholar Rock Holding Corporation are subject to a Lock-Up Agreement Ending on 11-DEC-2023.	11/12	CI
Certain Stock Options of Scholar Rock Holding Corporation are subject to a Lock-Up Agreement Ending on 11-DEC-2023.	11/12	CI
Certain Common Stock of Scholar Rock Holding Corporation are subject to a Lock-Up Agreement Ending on 11-DEC-2023.	11/12	CI

Chart Scholar Rock Holding Corporation

Duration

Period

More charts

Company Profile

Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of medicines for the treatment of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. The Company's product candidate includes apitegromab, an inhibitor of the activation of latent myostatin for the treatment of spinal muscular atrophy (SMA) and is in the treatment of other myostatin-related disorders. Its product candidate also includes SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 (TGF?1) for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies. The Company is advancing multiple antibody profiles toward product candidate selection, including antibodies that selectively inhibit the activation of latent TGF?1 in the context of fibrotic extracellular matrix and that avoid perturbing TGF?1 presented by cells of the immune system.

Sector

Biotechnology & Medical Research

Calendar

04/06/2024 - American Society of Clinical Oncology Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.33 USD

Average target price

26.25 USD

Spread / Average Target

+154.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SCHOLAR ROCK HOLDING CORPORATION	-47.21%	824M
VERTEX PHARMACEUTICALS INCORPORATED	+8.98%	115B
REGENERON PHARMACEUTICALS, INC.	+9.80%	105B
BIONTECH SE	-12.59%	22.71B
ARGENX SE	+2.21%	21.83B
GENMAB A/S	-10.88%	18.18B
WUXI APPTEC CO., LTD.	-41.92%	16.52B
BEIGENE, LTD.	-16.28%	16.01B
NEUROCRINE BIOSCIENCES, INC.	+1.70%	14.14B
SAREPTA THERAPEUTICS, INC.	+17.59%	10.71B

Bio Therapeutic Drugs